These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 27678025)

  • 1. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease.
    Lozupone M; Berardino G; Mollica A; Sardone R; Dibello V; Zupo R; Lampignano L; Castellana F; Bortone I; Stallone R; Daniele A; Altamura M; Bellomo A; Solfrizzi V; Panza F
    Expert Opin Investig Drugs; 2022 Aug; 31(8):759-771. PubMed ID: 35758153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 6. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
    Evin G
    BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
    Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
    Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies for Alzheimer's disease in clinical trials.
    Godyń J; Jończyk J; Panek D; Malawska B
    Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
    Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
    Querol-Vilaseca M; Sirisi S; Molina-Porcel L; Molina B; Pegueroles J; Ferrer-Raventós P; Nuñez-Llaves R; Dols-Icardo O; Balasa M; Iulita MF; Blesa R; Belbin O; Clarimon J; Fortea J; Gelpi E; Sánchez-Valle R; Lleó A
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12781. PubMed ID: 34825396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug candidates in clinical trials for Alzheimer's disease.
    Hung SY; Fu WM
    J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
    Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
    Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.